JP2019533695A5 - - Google Patents

Download PDF

Info

Publication number
JP2019533695A5
JP2019533695A5 JP2019522925A JP2019522925A JP2019533695A5 JP 2019533695 A5 JP2019533695 A5 JP 2019533695A5 JP 2019522925 A JP2019522925 A JP 2019522925A JP 2019522925 A JP2019522925 A JP 2019522925A JP 2019533695 A5 JP2019533695 A5 JP 2019533695A5
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
composition according
identified
acute kidney
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019522925A
Other languages
English (en)
Japanese (ja)
Other versions
JP7100030B2 (ja
JP2019533695A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/058787 external-priority patent/WO2018081578A1/en
Publication of JP2019533695A publication Critical patent/JP2019533695A/ja
Publication of JP2019533695A5 publication Critical patent/JP2019533695A5/ja
Application granted granted Critical
Publication of JP7100030B2 publication Critical patent/JP7100030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019522925A 2016-10-28 2017-10-27 腎機能の改善のためのtimp-2に対する抗体の使用 Active JP7100030B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662414479P 2016-10-28 2016-10-28
US62/414,479 2016-10-28
PCT/US2017/058787 WO2018081578A1 (en) 2016-10-28 2017-10-27 Use of antibodies to timp-2 for the improvement of renal function

Publications (3)

Publication Number Publication Date
JP2019533695A JP2019533695A (ja) 2019-11-21
JP2019533695A5 true JP2019533695A5 (enExample) 2021-02-25
JP7100030B2 JP7100030B2 (ja) 2022-07-12

Family

ID=62024058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522925A Active JP7100030B2 (ja) 2016-10-28 2017-10-27 腎機能の改善のためのtimp-2に対する抗体の使用

Country Status (7)

Country Link
US (1) US20190263926A1 (enExample)
EP (1) EP3532101B1 (enExample)
JP (1) JP7100030B2 (enExample)
CN (1) CN110352073A (enExample)
AU (1) AU2017348365A1 (enExample)
ES (1) ES2908239T3 (enExample)
WO (1) WO2018081578A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ628843A (en) 2008-10-21 2016-02-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5763098B2 (ja) 2009-12-20 2015-08-12 アスチュート メディカル,インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
WO2011162821A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA3158996C (en) 2013-01-17 2024-06-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105917229B (zh) 2013-12-03 2019-04-26 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
US11346846B2 (en) 2017-02-06 2022-05-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN110709103B (zh) 2017-04-05 2024-02-02 机敏医药股份有限公司 用于生物学样品中具有改善的性能的timp2的测定法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US459007A (en) 1891-09-08 Porte
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever N.V., Rotterdam Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク. 免疫したゼノマウス(XenoMouse)に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
NZ628843A (en) 2008-10-21 2016-02-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5763098B2 (ja) 2009-12-20 2015-08-12 アスチュート メディカル,インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
WO2012044620A2 (en) * 2010-09-30 2012-04-05 Nitto Denko Corporation Modulation of timp1 and timp2 expression
CA3158996C (en) * 2013-01-17 2024-06-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2015021308A1 (en) * 2013-08-07 2015-02-12 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples
CN105917229B (zh) * 2013-12-03 2019-04-26 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物

Similar Documents

Publication Publication Date Title
JP2019533695A5 (enExample)
Cheruku et al. Acute kidney injury after cardiac surgery: prediction, prevention and management
Brochard et al. An official ATS/ERS/ESICM/SCCM/SRLF statement: prevention and management of acute renal failure in the ICU patient: an international consensus conference in intensive care medicine
Bagshaw et al. Acute kidney injury in critical illness
Cárdenas Hepatorenal syndrome: a dreaded complication of end-stage liver disease
Parida et al. Cardiac surgery-associated acute kidney injury
Stafford-Smith et al. Acute kidney injury and chronic kidney disease after cardiac surgery
Karvellas et al. Acute kidney injury in cirrhosis
Al-Khafaji et al. Hepatorenal disorders
JP2023002547A (ja) 慢性腎疾患の治療のためのデュラグルチド
Sriperumbuduri et al. New insights into mechanisms of acute kidney injury in heart disease
Fadaii et al. Prevalence of pulmonary hypertension in patients undergoing hemodialysis
Fiaccadori et al. Ultrafiltration in heart failure
Mazumder et al. The diagnosis and non-pharmacological management of acute kidney injury in patients with cirrhosis
Biegus et al. Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED‐AHF): A prospective, randomized, mechanistic study
Domi et al. From pre-existing renal failure to perioperative renal protection: the anesthesiologist’s dilemmas
Pham et al. Sickle cell disease
Tang et al. Clinical practice guidelines for the provision of renal service in Hong Kong: general nephrology
Abdelwahed et al. Effects of transjugular intrahepatic portosystemic shunt on renal and pulmonary function in hepatic decompensation with and without hepatorenal and hepatopulmonary syndromes: A review
N Kampaktsis et al. Strategies to avoid TAVI-related acute kidney injury
Durdu et al. Promising utilization areas of therapeutic plasmapheresis in cardiovascular surgery practice
Guerrero-Domínguez et al. Perioperative renal protection strategies in liver transplantation
Kruiswijk et al. The safety of indocyanine green in patients with advanced chronic kidney disease or kidney transplantation: a scoping review
Wang et al. Clinical characteristics of hepatopulmonary syndrome and hepatorenal syndrome and associated therapeutic potential of transjugular intrahepatic portosystemic shunt
Tam et al. Acute Kidney Injury and Renal Replacement Therapy: A Review and Update for the Perioperative Physician